![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1371965
¼¼°èÀÇ ¹ÙÀÌ¿À¼¾¼ ½ÃÀå ¿¹Ãø(-2030³â) : À¯Çüº°, Á¦Ç°º°, ±â¼úº°, ¿ëµµº°, Áö¿ªº° ¼¼°è ºÐ¼®Biosensor Market Forecasts to 2030 - Global Analysis By Type (Embedded Device, Sensor Patch and Other Types), Product (Non-wearable Biosensors and Wearable Biosensors), Technology, Application and By Geography. |
Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ ¹ÙÀÌ¿À¼¾¼ ½ÃÀåÀº 2023³â¿¡ 294¾ï 8,000¸¸ ´Þ·¯¸¦ Â÷ÁöÇÏ¸ç ¿¹Ãø ±â°£ Áß CAGRÀº 10.0%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 574¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.
¹ÙÀÌ¿À¼¾¼´Â ÁÖ·Î »ýü ºÐÀÚ, ¹ÚÅ׸®¾Æ µî »ý¹°ÇÐÀû ¹°ÁúÀÇ Á¸Àç¿Í ³óµµ¸¦ °¨ÁöÇϰųª °¨ÁöÇÏ´Â µ¥ »ç¿ëµÇ´Â ÀÇ·á±â±âÀÔ´Ï´Ù. »ýü ¹ÝÀÀÀ» Àü±â ½ÅÈ£·Î º¯È¯ÇÒ ¼ö ÀÖ´Â ºÐ¼® ÅøÀÔ´Ï´Ù. ½Äǰ ¹× À½·á, ȯ°æ ¸ð´ÏÅ͸µ, ȨÄɾî Áø´Ü ¹× ±âŸ ³ª³ë ±â°è½Ä ¹ÙÀÌ¿À ¼¾¼´Â ¹ÙÀÌ¿À ¼¾¼°¡ »ç¿ëµÇ´Â ¸î °¡Áö ºÐ¾ß¿¡ ºÒ°úÇÕ´Ï´Ù.
±¹Á¦´ç´¢º´¿¬¸Í¿¡ µû¸£¸é ´ç´¢º´Àº ¸Å³â ¾à 8.0%¾¿ Áõ°¡Çϰí ÀÖÀ¸¸ç, 2035³â±îÁö 5¾ï 9,000¸¸ ¸í ÀÌ»óÀÌ ´ç´¢º´¿¡ °É¸± °ÍÀ¸·Î ¿¹»óµÇ¾î ¿¹Ãø ±â°£ Áß ½ÃÀåÀÌ ±Þ°ÝÇÏ°Ô È®´ëµÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
¹ÙÀÌ¿À¼¾¼´Â Áúº´ÀÇ ¿¹ÈÄ¿Í È¯ÀÚÀÇ »ýÁ¸ÀÌ Á¶±â¿¡ Á¤È®ÇÑ Áúº´ Áø´Ü¿¡ ´Þ·ÁÀִٴ Ư¼öÇÑ ±âÁØÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÃÖ±Ù ¼ö³â°£ °£´ÜÇϰí ÀÏȸ¿ëÀ̸ç, »ç¿ëÇϱ⠽±°í, ºñ¿ë È¿À²ÀûÀ̸ç, ÀÀ´ä ½Ã°£ÀÌ ºü¸¥ Àåºñ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½ÇÇè½Ç¿¡¼´Â ÀÚ°¡ °Ë»ç, ÇöÀå °Ë»ç, Æ÷µµ´ç ¸ð´ÏÅ͸µ¿¡ »ç¿ëµÇ´Â ¹ÙÀÌ¿À¼¾¼°¡ »ç¿ëµÇ°í ÀÖÀ¸¸ç, »ó¾÷ÀûÀ¸·Î °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ÙÀÌ¿À¼¾¼´Â Àü±âÈÇÐÀû ¹× ±¤ÇÐÀû Àü´Þ ¹æ½ÄÀ» »ç¿ëÇÏ¿© Æ÷µµ´ç, ¿ä¼Ò, Å©·¹¾ÆÆ¼´Ñ, Á¥»ê ¹× ±âŸ ¹°ÁúÀ» ÃøÁ¤ÇÕ´Ï´Ù. ¶ÇÇÑ ¹ÙÀÌ¿À¼¾¼´Â ¾Ï, ´ç´¢º´, ½ÉÇ÷°ü°è Áúȯ µî ÇコÄÉ¾î ºÐ¾ßÀÇ ¿©·¯ ºÐ¾ß¿¡¼ ÀÀ¿ëµÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áúº´ÀÇ Á¶±â ¹ß°ßÀ» À§ÇÑ ¹ÙÀÌ¿À¼¾¼ÀÇ »ç¿ëÀº ¼¼°è¿¡¼ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¼¾¼´Â º´¿ø, ÀçÅà ȯÀÚ ¹× º´¿ø ¿ÜÀÇ È¯°æ¿¡¼ °£º´ÀÎÀÇ »õ·Î¿î ¿ëµµ¿¡ ÀûÇÕÇϸç, ÀÌ´Â ¹ÙÀÌ¿À¼¾¼ »ç¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
¹ÙÀÌ¿À¼¾¼ ±â¼úÀÇ °³¹ß, »ý»ê ¹× µµÀÔ¿¡´Â º¹ÀâÇÑ °øÁ¤, Ư¼ö Àç·á ¹× ÷´Ü Á¦Á¶ ±â¼úÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ Àüü ºñ¿ëÀ» Áõ°¡½Ãŵ´Ï´Ù. ÀÌ·¯ÇÑ ºñ¿ëÀº ƯÈ÷ ÀÚ¿øÀÌ ÇÑÁ¤µÈ ÀÇ·á ȯ°æ°ú ºñ¿ë È¿À²¼º¿¡ ¹Î°¨ÇÑ »ê¾÷¿¡¼ º¸±ÞÀÇ À庮ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¼¾¼¸¦ º¸´Ù ³Î¸® º¸±ÞÇÏ°í ´Ù¾çÇÑ ¿ëµµ¿¡ Àû¿ëÇϱâ À§Çؼ´Â Àú·ÅÇÑ °¡°ÝÀÌ ÇʼöÀûÀ̸ç, ÀÌ·¯ÇÑ ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎÀ» ±Øº¹ÇÏ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϱâ À§Çؼ´Â ±â¼ú ¹ßÀü°ú Á¦Á¶ °øÁ¤ÀÇ °£¼Òȸ¦ ÅëÇØ ºñ¿ëÀ» Àý°¨ÇÏ·Á´Â ³ë·ÂÀÌ ÇʼöÀûÀÔ´Ï´Ù.
¹ÙÀÌ¿À¼¾¼´Â Á¦¾à »ê¾÷¿¡¼ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ÀǾàǰ °³¹ß, ¸ð´ÏÅ͸µ ¹× ǰÁú °ü¸®¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀǾàǰ °³¹ß¿¡¼ ¹ÙÀÌ¿À¼¾¼´Â ÀáÀçÀûÀÎ ¾à¹° ÈÇÕ¹°°ú »ýü ºÐÀÚ °£ÀÇ »óÈ£ÀÛ¿ëÀ» ¿¬±¸ÇÏ¿© ¾à¹° È常¦ ½Äº°Çϰí ÃÖÀûÈÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡¼ ¹ÙÀÌ¿À¼¾¼´Â Åõ¿©·®À» ÃÖÀûÈÇϰí Á¤È®ÇÑ ¾à¹° ¹æÃâÀ» º¸ÀåÇÏ¿© Ä¡·á È¿°ú¸¦ ³ôÀÏ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. Á¦¾à »ê¾÷ÀÇ Ç°Áú °ü¸®´Â ¹èÄ¡ Å×½ºÆ® ¹× °ËÁõ¿¡¼ ¹ÙÀÌ¿À¼¾¼¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¼¾¼´Â ƯÁ¤ »ýü ºÐÀÚ¸¦ Á¤È®ÇÏ°Ô °¨ÁöÇϰí Á¤·®ÈÇÏ¿© ÀǾàǰÀÇ ¼øµµ, ¿ª°¡ ¹× ¾ÈÁ¤¼ºÀ» º¸ÀåÇÕ´Ï´Ù. µû¶ó¼ ¹ÙÀÌ¿À¼¾¼´Â Á¦¾à ºÐ¾ß¿¡¼ ½Å¾à °³¹ß, °³¹ß, ǰÁú º¸ÁõÀ» Áö¿øÇÏ°í ±Ã±ØÀûÀ¸·Î ÀÇ·á ¹ßÀü°ú ȯÀÚ °á°ú °³¼±¿¡ ±â¿©ÇÒ ¼ö ÀÖ´Â ¸Å¿ì À¯¿ëÇÑ ÅøÀ» Á¦°øÇÕ´Ï´Ù.
µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã¿¡ ´ëÇÑ ¿ì·Á´Â ¹ÙÀÌ¿À¼¾¼ ½ÃÀå¿¡ Å« Á¦¾à ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¼¾¼´Â ¹Î°¨ÇÑ °Ç° °ü·Ã µ¥ÀÌÅ͸¦ ¼öÁýÇϰí Àü¼ÛÇϱ⠶§¹®¿¡ µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ¹× º¸¾È¿¡ ´ëÇÑ ¿ì·Á°¡ Ä¿Áö°í ÀÖ½À´Ï´Ù. »ç¿ëÀÚµéÀº °³ÀÎ °Ç°Á¤º¸ÀÇ ¾Ç¿ë°ú ¹«´Ü Á¢±Ù °¡´É¼ºÀ» ¿ì·ÁÇØ ¹ÙÀÌ¿À¼¾¼, ƯÈ÷ ¿þ¾î·¯ºíÀ» µµÀÔÇÏ´Â °ÍÀ» ²¨¸®°í ÀÖ½À´Ï´Ù. µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ±ÔÁ¦°¡ °ÈµÇ°í ÀÌ·¯ÇÑ ¿ì·Á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó »ç¿ëÀÚÀÇ ½Å·Ú¿Í ¼ö¿ë¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. µû¶ó¼ È¿°úÀûÀÎ µ¥ÀÌÅÍ ¾ÏÈ£È, µ¥ÀÌÅÍ Ã³¸® °üÇàÀÇ °³¹æ¼º, ¾ö°ÝÇÑ °³ÀÎ Á¤º¸ º¸È£¹ý Áؼö¸¦ ÅëÇØ ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇÔÀ¸·Î½á ¿ì·Á¸¦ ¿ÏÈÇϰí ÀÇ·á ¹× ±âŸ »ê¾÷¿¡¼ ¹ÙÀÌ¿À¼¾¼ÀÇ Æø³ÐÀº äÅÃÀ» ÃËÁøÇÏ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.
COVID-19 Àü¿°º´Àº ¼¼°è ¹ÙÀÌ¿À¼¾¼ ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÆÀ¸¸ç, COVID-19ÀÇ À¯Çà¿¡ µû¶ó ¸¹Àº Çаè¿Í ÁÖ¿ä ±â¾÷ÀÌ ¹ÙÀÌ¿À¼¾¼ ¿¬±¸°³¹ßÀ» ´ëÆø °ÈÇß½À´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹°úÇÐÁøÈïÇùȸ(AAAS)¿¡ µû¸£¸é ½ºÀ§½º ¿¬¹æÀç·á°úÇбâ¼ú¿¬±¸¼Ò¿Í Ã븮È÷°ø°ú´ëÇÐÀÇ Áø¿Ï°ú ±×ÀÇ ÆÀÀº SARS-CoV-2¸¦ ƯÀÌÀûÀ¸·Î ½Äº°ÇÒ ¼ö ÀÖ´Â POC ¹ÙÀÌ¿À¼¾¼¸¦ °³¹ßÇß½À´Ï´Ù. ÀÌ ¼¾¼¸¦ ÀÓ»ó Áø´Ü¿¡ »ç¿ëÇÏ¿© °ø±â ÁßÀÇ ¹ÙÀÌ·¯½º ¾çÀ» ½Ç½Ã°£À¸·Î ¸ð´ÏÅ͸µÇÏ´Â °ÍÀº ±âÁ¸ÀÇ ½ÇÇè½Ç °Ë»ç¸¦ ´ëüÇÒ ¼ö ÀÖÁö¸¸ ´ëüÇÒ ¼ö´Â ¾ø½À´Ï´Ù. ¸¶Âù°¡Áö·Î, COVID-19 °Ë»ç¸¦ À§ÇÑ ¹ÙÀÌ¿À¼¾¼¸¦ °³¹ßÇϱâ À§ÇØ ¸¶ÀÌÅ©·Î Àü±â±â°è ½Ã½ºÅÛ ¹× ¼¾¼¸¦ Á¦Á¶ÇÏ´Â ·Î±×¹ë¸® ¸¶ÀÌÅ©·Îµð¹ÙÀ̽º(Rogue Valley Micro Devices)´Â Ä®µ¥¾Æ ¹ÙÀÌ¿À & Çì¹Í½º(Caldea Bio & Hemics)¿Í °°Àº Ãʱ⠴ܰèÀÇ È¸»ç¿Í Çù·ÂÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼ ¿¹Ãø ±â°£ Áß ÀÌ·¯ÇÑ ¿äÀεéÀÌ ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÓº£µðµå ±â±â ºÎ¹®Àº ÇコÄɾî, ȯ°æ ¸ð´ÏÅ͸µ, ½Äǰ ¹× À½·á, CE(Consumer Electronics) µî ¿©·¯ »ê¾÷¿¡¼ ÀÓº£µðµå ¹ÙÀÌ¿À¼¾¼¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÔ¿¡ µû¶ó ÀÓº£µðµå ±â±â ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¹ÙÀÌ¿À¼¾¼ÀÇ Áß¿äÇÑ ÇÏÀ§ ÁýÇÕÀÎ ÀÓº£µðµå µð¹ÙÀ̽º´Â ´Ù¾çÇÑ ½Ã½ºÅÛ, Á¦Ç° ¶Ç´Â Ç÷§Æû¿¡ ¹ÙÀÌ¿À¼¾¼ ±â¼úÀ» ÅëÇÕÇÏ¿© ±â´ÉÀ» Çâ»ó½ÃŰ°í ½Ç½Ã°£ ¸ð´ÏÅ͸µ ¹× ºÐ¼®À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ¹ÙÀÌ¿À¼¾¼´Â ´ç´¢º´ °ü¸®¸¦ À§ÇÑ ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ, ¿þ¾î·¯ºí °Ç° ÃßÀû±â, ȯ°æ ¿À¿° ¸ð´ÏÅ͸µ, ½Äǰ »ê¾÷ÀÇ ½º¸¶Æ® Æ÷Àå µî¿¡ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù.
ÇコÄÉ¾î ºÎ¹®Àº ¿¹Ãø ±â°£ Áß À¯¸®ÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹ÙÀÌ¿À¼¾¼ ½ÃÀåÀÇ ÇコÄÉ¾î ºÎ¹®Àº ȯÀÚ Ä¡·á, Áúº´ °ü¸® ¹× Áø´Ü¿¡ Çõ½ÅÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¼¾¼´Â ´ç´¢º´ Ç÷´ç ¸ð´ÏÅ͸µ, ½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿ °¨Áö, ÀӽŠ°Ë»ç, °¨¿° Áø´Ü, ¾à¹° ¼öÁØ ¸ð´ÏÅ͸µ µî¿¡ ±¤¹üÀ§ÇÏ°Ô Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. Áß¿äÇÑ ¹ßÀü Áß Çϳª´Â »ýü ½ÅÈ£, Æ÷µµ´ç ¼öÄ¡ ¹× ±âŸ °Ç° ¸Å°³ º¯¼ö¸¦ Áö¼ÓÀûÀ¸·Î ºñħ½ÀÀûÀ¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â ¿þ¾î·¯ºí ¹ÙÀÌ¿À¼¾¼ÀÇ °³¹ßÀÔ´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ¿þ¾î·¯ºíÀº ȯÀÚ¿Í ÀÇ·á Àü¹®°¡ ¸ðµÎ¿¡°Ô ±ÍÁßÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© ¸¸¼ºÁúȯÀÇ ¿¹¹æÀû °ü¸®¿Í Àû½Ã¿¡ °³ÀÔÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÀÇ·á ¼ºñ½º Á¦°ø¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ȯÀÚ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áø ÇコÄÉ¾î ºÐ¾ßÀÇ ¹ÙÀÌ¿À¼¾¼´Â Áß¿äÇÏ°í ¼ºÀåÇÏ´Â ½ÃÀå ºÎ¹®ÀÔ´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀº Àα¸°¡ ¸¹°í ´Ù¾çÇÑ »ýȰ½À°üº´ÀÇ ¹ß»ý·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÃßÁ¤ ±â°£ Áß °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ Áö¿ª¿¡¼´Â ÀçÅÃÄ¡·á, ÇöÀå Áø·á ¼ºñ½º ¹× ±âŸ ¼ºÀÎ ÇコÄÉ¾î »ç¾÷¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¿Ü·¡ ȯÀÚ Ä¡·á ¸ðµ¨À» °³¹ßÇÏ¿© ÀÔ¿ø ±â°£À» ÁÙÀÌ·Á´Â Á¤ºÎÀÇ ±¸»óµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ °¢±¹ Á¤ºÎ, WHO, CHAI(Clinton Health Access Initiative, Inc.)¿Í °°Àº ±â°ü¿¡¼ ´Ù¾çÇÑ º¸°Ç ±¸»óÀ» ½ÃÀÛÇÑ °Íµµ ÀÌ Áö¿ªÀÇ Åë°è¿¡ ÈûÀ» ½Ç¾îÁÖ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼¼°è ºê·£µåÀÇ Á¸Àç¿Í °¡¿ë¼º, ÇöÁö ¹× ±¹³» ºê·£µå¿ÍÀÇ °æÀïÀ¸·Î ÀÎÇØ Á÷¸éÇÑ °úÁ¦, ±¹³» °ü¼¼ÀÇ ¿µÇâ, ¹«¿ª °æ·Î µîÀÌ Áö¿ª µ¥ÀÌÅÍ¿¡ ´ëÇÑ ¿¹Ãø ºÐ¼®À» Á¦°øÇÒ ¶§ °í·ÁµË´Ï´Ù.
ºÏ¹Ì´Â ¿¹Ãø ±â°£ Áß ¼öÀͼº ÀÖ´Â ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ª¿¡¼´Â ½Äǰ ǰÁú ÁöÇ¥¸¦ ÃßÀûÇϱâ À§ÇÑ ¹ÙÀÌ¿À¼¾¼ÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» Áö¿øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀüÀÚ ÀÇ·á ±â·Ï(EMR) ½ÃÀå ħÅõÀ² Áõ°¡¿Í ¼ÒÇüÈµÈ Áø´Ü Àåºñ ½ÃÀå °³Ã´Àº ¿¹Ãø ±â°£ Áß ½ÃÀå È®´ë¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ¹Ì±¹¿¡´Â ´ë±â¿À¿°¹æÁö¹ý, ¼öÁú¿À¿°¹æÁö¹ý, ±¹°¡È¯°æÁ¤Ã¥¹ý µîÀÌ Á¸ÀçÇÏ¿© ºÏ¹Ì ½ÃÀå È®´ë ±âȸ°¡ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ºÏ¹ÌÀÇ POC ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ºü¸£°í, ½±°í, Á¤È®Çϰí, ÈÞ´ë °¡´ÉÇϸç, Àúºñ¿ëÀÇ ºÐ¼® ±â±â¿¡ ´ëÇÑ °ü½ÉÀº ÀÌ Áö¿ªÀÇ ¹ÙÀÌ¿À¼¾¼ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀÔ´Ï´Ù.
According to Stratistics MRC, the Global Biosensor Market is accounted for $29.48 billion in 2023 and is expected to reach $57.44 billion by 2030 growing at a CAGR of 10.0% during the forecast period. Biosensors are medical devices that are used primarily to sense or detect the presence or concentration of biological material, such as a biomolecule or a bacterium. They are analytical tools that can transform a biological reaction into an electrical signal. Food and beverages, environmental monitoring, home care diagnostics, and other nanomechanical biosensors are just a few areas where biosensors are used.
According to the International Diabetic Federation, diabetes is rising at an annual rate of about 8.0 percent. More than 590 million people are expected to develop diabetes by 2035, implying that the market would increase rapidly throughout the projected period.
Biosensors have specialised criteria, which include that the prognosis of diseases and the survival of patients depend on an early and accurate disease diagnosis. Simple, disposable, user-friendly, and cost-effective devices with quick response times have become much more in demand in recent years. In laboratories, biosensors for self-testing, point-of-care testing, and glucose monitoring are being used and commercially developed. These biosensors measure glucose, urea, creatinine, lactate, and other substances using electrochemical and optical modes of transduction. Moreover, applications for biosensors can be found in many areas of the healthcare sector, including cancer, diabetes, and cardiovascular conditions. The use of biosensors for these diseases' early detection has increased as their prevalence around the globe has increased. Biosensors are ideal for new applications in hospitals, by patients at home, and by carers in non-hospital settings, thus boosting the use of biosensors.
The development, production, and implementation of biosensor technology involve complex processes, specialized materials, and advanced manufacturing techniques, driving up the overall cost. These expenses pose a barrier to widespread adoption, especially in resource-limited healthcare settings and industries sensitive to cost-efficiency. Affordability is crucial for broader accessibility and integration of biosensors into various applications, and efforts to mitigate costs through technological advancements and streamlined manufacturing processes are essential to overcoming this restraint and promoting market growth.
Biosensors have a vital role in the pharmaceutical industry, contributing to drug development, monitoring, and quality control. During drug development, biosensors are employed to study the interactions between potential drug compounds and biological molecules, aiding in the identification and optimisation of drug candidates. In drug delivery systems, biosensors assist in optimising dosages and ensuring precise drug release, enhancing therapeutic outcomes. Quality control within the pharmaceutical industry heavily relies on biosensors for batch testing and validation. Biosensors can accurately detect and quantify specific biomolecules, ensuring the purity, potency, and stability of drugs. Thus, biosensors offer invaluable tools in the pharmaceutical sector, supporting drug discovery, development, and quality assurance, ultimately contributing to the advancement of healthcare and the improvement of patient outcomes.
Data privacy concerns present a significant restraint in the biosensor market. As biosensors collect and transmit sensitive health-related data, there's growing apprehension regarding data privacy and security. Users worry about potential misuse or unauthorised access to their personal health information, leading to reluctance to adopt biosensors, particularly wearables. Stricter data privacy regulations and increasing awareness of these concerns impact user trust and acceptance. Therefore, it is crucial to reduce concerns and promote a wider adoption of biosensors in healthcare and other industries by addressing these issues through effective data encryption, openness in data handling practices, and adherence to strict privacy legislation.
The COVID-19 epidemic had a huge impact on the world biosensor market. Numerous academic institutions and significant businesses have significantly raised their biosensor research and development in response to the COVID-19 epidemic. For instance, Jing Wang and his team at the Swiss Federal Laboratories for Materials Science and Technology and ETH Zurich have created a point-of-care biosensor that can specifically identify SARS-CoV-2, according to the American Association for the Advancement of Science (AAAS). The use of this sensor for clinical diagnosis and real-time monitoring of virus content in the air offers an alternative to traditional laboratory testing but does not replace it. Similarly, to create biosensors for COVID-19 testing, Rogue Valley Microdevices-a producer of microelectromechanical systems and sensors-is collaborating with early-stage companies like Cardea Bio & Hememics. Therefore, it is projected that these factors will spur market expansion throughout the forecast period.
The Embedded Device segment is estimated to hold the largest share, due to the significant surge in demand for embedded biosensors across multiple industries, such as healthcare, environmental monitoring, food and beverage, and consumer electronics. Embedded devices, a crucial subset of biosensors, involve the integration of biosensor technology into various systems, products, or platforms, enhancing their functionality and enabling real-time monitoring and analysis. Furthermore, these biosensors find applications in continuous glucose monitoring for diabetes management, wearable health trackers, environmental pollution monitoring, and smart packaging in the food industry, among others.
The Healthcare segment is anticipated to have lucrative growth during the forecast period. The healthcare segment of the biosensors market is witnessing a transformative impact on patient care, disease management, and diagnostics. Biosensors have found extensive applications in glucose monitoring for diabetes, cardiac biomarker detection, pregnancy testing, infectious disease diagnosis, and drug-level monitoring. One of the significant advancements is the development of wearable biosensors, which facilitate continuous and non-invasive monitoring of vital signs, glucose levels, and other health parameters. In addition to this, these wearables provide valuable data to both patients and healthcare professionals, enabling proactive management of chronic conditions and timely interventions. With the potential to revolutionise healthcare delivery and improve patient outcomes, biosensors in the healthcare sector represent a vital and expanding market segment.
Asia Pacific commanded the largest market share during the extrapolated period, due to the region's vast population base and rising rates of various lifestyle disorders. Increasing demand for home healthcare, point-of-care services and other adult-focused healthcare enterprises in this region, as well as government initiatives to reduce hospital stays by developing outpatient care models. Regional statistics are also being fuelled by the launch of numerous health initiatives by national governments, the WHO, and organisations like Clinton Health Access Initiative, Inc. (CHAI). Additionally, the presence and availability of global brands and the challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the region data.
North America is expected to witness profitable growth over the projection period. Increased use of biosensors in this area for tracking food quality indicators is anticipated to support market growth. A rise in the market penetration of electronic medical records (EMR) and the development of miniaturised diagnostic equipment are predicted to drive market expansion over the forecasted period. In addition, the existence of the Clean Air Act, Clean Water Act, and National Environmental Policy Act in the U.S. is expected to open up opportunities for market expansion in North America. Moreover, the increase in demand for POC technologies in North America and the focus on rapid, simple, accurate, portable, and low-cost analytical instruments propel the market growth for the biosensors market in the region.
Some of the key players in the Biosensor Market include: Bio-rad Laboratories, Nova biomedical, Acon laboratories, Eastprint incorporated, SD biosensor, Medtronic, Universal Biosensors, Conductive technologies, F. Hoffmann-La Roche Ltd, Innovative Sensor Technology AG, Pinnacle Technology, Abbott Laboratories, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Biosensors International Group, Ltd, Dexcom, Inc., QTL Biosystems, Danaher Corporation, DuPont Biosensor Materials and Johnson & Johnson.
In April 2023, Medtronic plc announced that the US FDA had approved its 'MiniMed 780G' system with the Guardian 4 sensor requiring no fingersticks while in SmartGuard technology. The system provides insulin to account for situations where users occasionally forget to bolus or underestimate the number of carbs in their meal. It has been approved for users of and above seven years of age with type 1 diabetes.
In March 2022, Nova Biomedical launched the Nova Max Pro Creatinine/eGFR Meter System, a tool for improving kidney care through kidney function screening and early kidney disease detection in POC settings outside the hospital, in all CE countries. The Nova Max Pro meter and creatinine biosensor measure blood creatinine and calculate estimated glomerular filtration rate (eGFR) from a 1.2 microliter capillary fingerstick blood sample in 30 seconds.
In January 2022, Roche and Sysmex signed a Global Business Partnership Agreement (GBP) to supply hematological diagnostic services. Using IT technology, the new cooperation aims to enhance clinical decision-making and consumer experience. This long-standing, fruitful collaboration is still going strong, offering hematological diagnostic improvements to labs all over the world.